Table 3.
OMD on-going phase III randomized controlled trials
| Study | Phase | Type of cancer | Intervention | Estimated completion date | Primary endpoint |
|---|---|---|---|---|---|
| NCT05278052 | III | NSCLC | Standard maintenance therapy + SBRT | 2028 | 2 year—OS |
| VS | |||||
| Standard maintenance therapy alone | |||||
| NCT05377047 | III | Breast cancer | SBRT to all sites | 2027 | 3 year—OS |
| VS | |||||
| Standard first line systemic therapy | |||||
| NCT04983095 | III | Prostate cancer | SBRT to all sites + standard treatment | 2029 | Failure-free survival |
| VS | |||||
| Standard treatment | |||||
| NCT04498767 | III | Solid tumors | SBRT to all sites | 2030 | OS |
| VS | |||||
| Palliative RT | |||||
| NCT04495309 | III | Breast cancer | SBRT to all sites + Standard treatment | 2025 | PFS and QoL |
| VS | |||||
| Standard treatment | |||||
| NCT02417662 | III | NSCLC | SBRT to all sites + Standard treatment | 2022 | 3 year—OS |
| VS | |||||
| Standard treatment alone | |||||
| NCT04599686 | III | Prostate cancer | SBRT to all sites | 2025 | 1 year—ADT-free survival |
| VS | |||||
| ADT | |||||
| NCT04115007 | III | Prostate Cancer | SBRT to all sites + Standard treatment | 2027 | Castration-resistant prostate cancer free survival |
| VS | |||||
| Standard treatment | |||||
| NCT04646564 | III | Breast cancer | SBRT to all sites + Standard treatment | 2026 | 2 year—PFS |
| VS | |||||
| Standard treatment | |||||
| NCT03862911 | III | Solid tumors | SBRT to all sites + Standard treatment | 2028 | 5 year—OS |
| VS | |||||
| Standard treatment | |||||
| NCT03784755 | III | Prostate cancer | SBRT to all metastatic lesions and primary tumor + Standard treatment | 2025 | Failure-free survival |
| VS | |||||
| SBRT to primary tumor + Standard treatment | |||||
| NCT03721341 | III | Solid tumors | SBRT to all sites + Standard treatment | 2029 | OS |
| VS | |||||
| Standard treatment | |||||
| NCT05209243 | III | Prostate cancer | SBRT to all metastatic sites + ADT + Standard treatment + RT to primary tumor | 2026 | 2 year—PFS |
| VS | |||||
| ADT + RT to primary tumor + Second generation hormonal treatment | |||||
| NCT03827577 | III | NSCLC | SBRT to all sites + Lung resection + Standard treatment | 2022 | 5 year—OS |
| VS | |||||
| Standard treatment | |||||
| NCT05352178 | III | Prostate cancer | SBRT to all sites | 2032 | 5 year—Poly metastatic free survival |
| VS | |||||
| SBRT to all sites + ADT |
NSCLC Non-Small Cell Lung Cancer, PFS Progression Free Survival, OS Overall Survival, ADT Androgen Deprivation Therapy, RT Radiation Therapy, QoL Quality of Life